The Web-based Cancer Program Practice Profile Reports (CP3R) offer local providers comparative information to assess adherence to and consideration of standard of care therapies for major cancers. This reporting tool provides a platform from which to promote continuous practice improvement to improve quality of patient care at the local level and also permits hospitals to compare their care for these patients relative to that of other providers. The aim is to empower clinicians, administrators, and other staff to work cooperatively and collaboratively to identify problems in practice and delivery and to implement best practices that will diminish disparities in care across Commission on Cancer (CoC)-accredited cancer programs.

Learn more about CP3R.

MedStar Georgetown University Hospital CP3R Data 2014

HT - Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability Measure)

Comparison To:

EPR %

My Cancer Program95.6
My ACS Division (South Atlantic)93.6
My Census Region (South Atlantic)92.3
My CoC Program Type (ACAD)93.2
My State (DC)no data
All CoC Approved Programs93.2

BCSRT - Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability Measure)

Comparison To:

EPR %

My Cancer Program95.1
My ACS Division (South Atlantic)93.2
My Census Region (South Atlantic)91.8
My CoC Program Type (ACAD)92.8
My State (DC)no data
All CoC Approved Programs92.8

MASTRT - Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days of diagnosis) of breast cancer for women with >= 4 positive regional lymph nodes (Accountability Measure)

Comparison To:

EPR %

My Cancer Program100
My ACS Division (South Atlantic)91.3
My Census Region (South Atlantic)89.5
My CoC Program Type (ACAD)90.5
My State (DC)no data
All CoC Approved Programs90

12RLN - At Least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement Measure)

Comparison To:

EPR %

My Cancer Program90
My ACS Division (South Atlantic)90.9
My Census Region (South Atlantic)90.6
My CoC Program Type (ACAD)93.2
My State (DC)no data
All CoC Approved Programs91.3

RECRTCT - Preoperative chemo and radiation are administered for clinical AJCC T3N0, or Stage III; or Preoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer (Quality Improvement)

Comparison To:

EPR %

My Cancer Program100
My ACS Division (South Atlantic)89.1
My Census Region (South Atlantic)88.7
My CoC Program Type (ACAD)88.4
My State (DC)no data
All CoC Approved Programs88.6

G15RLN - At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)

Comparison To:

EPR %

My Cancer Program62.5
My ACS Division (South Atlantic)48.4
My Census Region (South Atlantic)49.7
My CoC Program Type (ACAD)65.8
My State (DC)no data
All CoC Approved Programs58

LNoSurg - Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)

Comparison To:

EPR %

My Cancer Program100
My ACS Division (South Atlantic)93.9
My Census Region (South Atlantic)93.1
My CoC Program Type (ACAD)92.1
My State (DC)no data
All CoC Approved Programs92.7

LCT - Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months  postoperatively, or it is recommended for surgically resected cases with pathologic lymph node-postive (pN1) and (pN2) NSCLC (Quality Improvement)

Comparison To:

EPR %

My Cancer Program100
My ACS Division (South Atlantic)91.6
My Census Region (South Atlantic)91.9
My CoC Program Type (ACAD)92.3
My State (DC)no data
All CoC Approved Programs92.9

nBx - Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)

Comparison To:

EPR %

My Cancer Program98.4
My ACS Division (South Atlantic)93.4
My Census Region (South Atlantic)92.4
My CoC Program Type (ACAD)92.9
My State (DC)no data
All CoC Approved Programs92.4